Collaborations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended			6 Months Ended		12 Months Ended
	Jul. 07, 2020	May 09, 2019	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unsatisfied performance obligation			$ 49,100			$ 49,100
Cost reimbursement payment received						5,800
Unbilled accounts receivable			1,700			1,700
Research and development			59,202		$ 45,767	$ 108,021	$ 87,994
Remaining research term of collaboration						1 year 3 months 18 days
Revenue recognized			25,650		16,513	$ 35,937	25,979
Deferred Revenue			5,900			5,900
Revenue Recognized						55,000
Milestone Two [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue			6,400			8,800
Unconstrained Consideration				$ 55,000				$ 55,000
Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognised			19,400
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 150,000
Collaboration agreement transaction price	150,000
Revenue recognized recorded in deferred revenue			25,700		9,900	35,900	17,600
Unsatisfied performance obligation			22,400	54,700		22,400		54,700
Revenue recognized						35,900		32,600
Sanofi Agreement | Milestone One [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognised				40,000
Sanofi Agreement | Milestone Two [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognised				15,000
Sanofi Agreement | Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	120,000
Revenue recognized recorded in deferred revenue					8,800		15,900
Sanofi Agreement | Collaboration Target 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	30,000
Revenue recognized recorded in deferred revenue					1,100		1,700
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,480,000
Commercial Milestone Payments	700,000
Sanofi Agreement | Minimum | IRAK4 Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,000,000
Commercial Milestone Payments	$ 400,000
Vertex Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unsatisfied performance obligation			0	$ 0		0		$ 0
Initial research term of collaboration		4 years
Extended research term of collaboration		1 year
Revenue recognized			$ 0		$ 6,600	$ 0	$ 8,400
Vertex Agreement | Series B-1 Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price		$ 55,900
Non refundable upfront payment received		$ 50,000
Issuance of shares, Shares		3,059,695
Stock issued price per share		$ 6.54
Preferred stock premium		$ 5,900
Vertex Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payments including development, regulatory and commercial milestones		$ 170,000